Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. - Wikidata - awgldk - TriplyDB

Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study.

Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study.

http://www.wikidata.org/entity/Q39883589

about

Rituximab in renal transplantation Desensitization: Overcoming the Immunologic Barriers to Transplantation Proliferative glomerulonephritis with monoclonal IgG deposits in two kidney allografts successfully treated with rituximab.Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study.IVIg treatment reduces catalytic antibody titers of renal transplanted patients A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation.Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients.B Cells, Antibodies, and More.Sensitized recipients exhibit accelerated but not hyperacute rejection of vascularized composite tissue allografts Anti-huCD20 antibody therapy for antibody-mediated rejection of renal allografts in a mouse model.Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy.Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients.Current immunosuppressive treatment after kidney transplantation.Targeting B cells and antibody in transplantation Update on the role of rituximab in kidney diseases and transplant.Therapeutic apheresis in children: special considerations.Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale.The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection.Detection of anti-HLA antibodies by solid-phase assay in kidney transplantation: friend or foe?The impact of donor-specific anti-HLA antibodies on late kidney allograft failure.B-cell regulation and its application to transplantation.Clinical efficacy of rituximab for acute rejection in kidney transplantation: a meta-analysis.Achieving incompatible transplantation through desensitization: current perspectives and future directions.Kidney transplantation in highly sensitized patients.Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study.Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.Combined induction therapy with rabbit antithymocyte globulin and rituximab in highly sensitized renal recipients.Benefits, efficacy, cost-effectiveness and infectious complications in transplant patients desensitized with intravenous immunoglobulin and anti-CD20 therapy.Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation.Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases?The effect of desensitization therapy in kidney transplantation.Biological Agents and Therapeutic Plasma Exchange: Can They Coexist in the Future?Mastering the risk of HLA antibodies in kidney transplantation: an algorithm based on pretransplant single-antigen flow bead techniques.Identifying Subphenotypes of Antibody-Mediated Rejection in Kidney Transplants.

P2860

Q27026434-9E28E215-1872-4DFB-ABC2-ABFD0A962299 Q30397952-919CA2E9-9B9E-4DE9-8AA9-E3348E547988 Q33783017-4694A6D2-74B1-40A8-B57C-269324FECD9C Q33842250-143707FD-E56B-41BD-92B7-EFB1F8CDC13A Q34962680-C7724345-F207-44D6-A3A2-7DF0103D0F31 Q35008036-AB313509-B4F7-435A-87A5-8E6F94379ADA Q35790552-904F476B-BD74-4C4E-9C00-BF27A0A53C00 Q36296061-D2D4CC64-2DF3-4A61-917D-96301335052B Q36432935-7F5238FB-74CB-48CB-BE81-B684F55341BA Q36778867-E9E4EFA1-CB4E-41D3-9B40-859B818A563E Q37252758-4DDB03AA-1873-48D9-A82F-9E34EB5F049B Q37660263-74D7D9FF-C21F-49D7-8A61-B9679765FA96 Q37827197-1C9F2526-8889-4195-93F2-6E5D2A3072ED Q37834028-FC8A4874-BBFC-4F59-BE77-C84A4EA7995E Q37888770-21AD85E4-B278-41C5-99D2-6F8B2FB22369 Q37970443-B1392F9B-DD91-410B-89B8-C88CD3A593D8 Q37978684-CEA01F5D-3A58-42B7-BAD7-A08BED71CC5D Q37990988-00247A07-EA58-4DB0-A32A-5E4BDBA086B9 Q37992871-019C2077-9F29-4EAD-9C5B-DDBAF6F00EB9 Q38001495-D85D1150-756B-4297-BA67-25D2C67194E3 Q38003049-78E75481-458C-4668-9048-4D3775CD8BF1 Q38126085-249ACDB3-3B86-49BF-A490-EA6E75F07C8D Q38163419-32FAE436-A687-494F-927D-2BEBF9B368C2 Q38445336-B1611B28-EB5B-4CB0-AB19-DF8FB6454547 Q38455229-620DD623-A337-438A-B9AB-1BACF395E061 Q39485911-C7E8EE1F-66BE-411D-A9EA-6E6265A4693F Q40523283-2F35F6F9-F865-475C-A748-EBCAD7B711C6 Q41258755-347782CB-BE90-4C06-AB58-E147CC94B696 Q41577805-BF6D78E1-FEE3-4350-8462-9DA308A4A744 Q42111937-CA245666-B606-4E63-948A-4BEAFA264B0C Q43406784-1E6E057E-1CC5-4821-99B5-AE4639911AF4 Q47172094-7E8A6B5D-2212-4858-BA3A-54902C2CD132 Q47340562-70C16F25-2D96-4203-A348-8F9A4584807E Q47800187-12318535-1650-41FF-A2C4-5F13FEE14070 Q51558707-A022678C-F17F-422A-AD9F-73F799AC8857 Q52890132-0C0FAC7C-C799-41C6-B75B-5EB1C86B7968

P2860

Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study.

http://www.wikidata.org/entity/Q39883589

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Combined posttransplant prophy ...... fic antibodies: a pilot study.

@en

Combined posttransplant prophy ...... fic antibodies: a pilot study.

@nl

type

label

Combined posttransplant prophy ...... fic antibodies: a pilot study.

@en

Combined posttransplant prophy ...... fic antibodies: a pilot study.

@nl

prefLabel

Combined posttransplant prophy ...... fic antibodies: a pilot study.

@en

Combined posttransplant prophy ...... fic antibodies: a pilot study.

@nl

P1433

Q39883589-F595A150-B3CA-4BCF-8204-FC915C730499

P1476

Q39883589-9C60C723-3057-4585-9D45-BAE348819316

P2093

Q39883589-11B5CFB1-FF83-41B9-98E8-1A4E552BBD56

Q39883589-3F88325A-6055-4755-89AA-B28F29F25453

Q39883589-4779A57A-FD1A-4406-99DC-6122A97B5383

Q39883589-6A5A5CFB-6C19-4833-A5F3-307EDF11C987

Q39883589-9CAFF89D-6E6B-4174-83DA-A08975CB6415

Q39883589-ACEDA013-006E-4F60-A2B8-27E4DEFD2D6F

Q39883589-B761E5F7-8E0A-4C17-83B5-7984EB32E03B

Q39883589-C6C0AE48-A2C0-429B-9CD3-533CCA36D032

Q39883589-D35DBA58-76DE-4EE0-9797-0E2A94503E65

Q39883589-F1BDD2C6-3172-4484-8BB9-C246B216ED95

P304

Q39883589-BDE67FC7-8DF2-4507-84CA-7068A6DEE7CA

P31

Q39883589-FC2972F8-CA03-49E7-9F67-B8C497D038AB

P356

Q39883589-E9B0B643-5FE7-4D55-93D4-55E396B7FAD3

P433

Q39883589-1463EE80-45FD-419B-8BCC-FFCC7E8ADBB6

P478

Q39883589-C5FAD361-0F96-45B6-9CBB-C70094A4B920

P50

Q39883589-0166EB24-BD9E-4F79-83A6-EAB39C7364BB

P577

Q39883589-11F91028-0D94-4764-A771-A54903437E9C

P698

Q39883589-AF9DE530-6846-4275-A3F2-BCAEF8E3FDC9

P921

Q39883589-C0AC70D9-77A9-455A-A4AA-94A8F086BCEA

P356

TP.0B013E3181DA1CC3

P1433

Transplantation

P1476

Combined posttransplant prophy ...... fic antibodies: a pilot study.

@en

P2093

Alexandre Loupy

http://www.w3.org/2001/XMLSchema#string

Caroline Suberbielle-Boissel

http://www.w3.org/2001/XMLSchema#string

Christophe Legendre

http://www.w3.org/2001/XMLSchema#string

Dany Anglicheau

http://www.w3.org/2001/XMLSchema#string

Dominique Charron

http://www.w3.org/2001/XMLSchema#string

Dominique Nochy

http://www.w3.org/2001/XMLSchema#string

Eric Thervet

http://www.w3.org/2001/XMLSchema#string

Frank Martinez

http://www.w3.org/2001/XMLSchema#string

Gary S Hill

http://www.w3.org/2001/XMLSchema#string

Julien Zuber

http://www.w3.org/2001/XMLSchema#string

P304

1403-1410

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/TP.0B013E3181DA1CC3

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P50

Patrick Bruneval

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20386362

http://www.w3.org/2001/XMLSchema#string

P921